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Summary
Splicing dysregulation is one of the molecular hallmarks of cancer. However, the underlying
molecular mechanisms remain poorly defined. Here we report the splicing factor RBM4
suppresses proliferation and migration of various cancer cells by specifically controlling cancer-
related splicing. Particularly, RBM4 regulates Bcl-x splicing to induce apoptosis, and co-
expression of Bcl-xL partially reverses the RBM4-mediated tumor suppression. Moreover, RBM4
antagonizes an oncogenic splicing factor, SRSF1, to inhibit mTOR activation. Strikingly, RBM4
expression is dramatically decreased in cancer patients, and RBM4 level is positively correlated
with improved survival. In addition to providing mechanistic insights of cancer-related splicing
dysregulation, this study establishes RBM4 as a tumor suppressor with therapeutic potentials and
clinical values as a prognostic factor.
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As one of the most prevalent mechanisms of gene regulation, alternative splicing (AS) plays
a vital role in intricate regulation of protein function, and splicing dysregulation is closely
associated with human cancers (David and Manley, 2010; Oltean and Bates, 2013;
Venables, 2006). Accumulating evidence suggests that aberrant AS elicits control over
major hallmarks of cancer, including apoptosis (Schwerk and Schulze-Osthoff, 2005),
epithelial-mesenchymal transition (Warzecha et al., 2010), and tumor invasion and
metastasis (Ghigna et al., 2008). The “cancerous” splicing variants of specific genes can
serve as molecular markers of cancer (e.g. CD44, WT1) (Venables et al., 2008) or directly
mediate cancer pathogenesis (e.g. BRCA1, p53) (Venables, 2006). However, mechanistic
details underlying deregulated splicing in cancer are still limited.
AS is generally regulated by multiple cis-elements that recruit splicing factors to affect
adjacent splice sites (ss) via various mechanisms (Matera and Wang, 2014; Matlin et al.,
2005; Wang and Burge, 2008). Common splicing factors include serine/arginine-rich (SR)
proteins that promote splicing by binding to exons but inhibit splicing by binding to introns
(Erkelenz et al., 2013; Wang et al., 2013), and hnRNPs that positively or negatively control
splicing in different pre-mRNA regions (Wang et al., 2012). The expression level,
localization, and activity of splicing factors generally determine splicing outcomes in
different tissues and cellular conditions. Therefore altered splicing factor activity is believed
to be a main cause of splicing dysregulation in cancer (Bechara et al., 2013; Shkreta et al.,
2013). For example, SRSF1 is a proto-oncogene that controls splicing of several cancer
related genes including those in mTOR pathway (Blaustein et al., 2005; Karni et al., 2007).
Since splicing dysregulation is one of molecular hallmarks of cancer (Oltean and Bates,
2013), specifically targeting splicing factors opens potential new avenues for cancer therapy
(Dehm, 2013).
We have previously identified RNA-binding motif 4 (RBM4) as a binding factor for a group
of intronic splicing regulatory elements that control AS of human genes (Wang et al., 2012).
Initially identified by sharing nuclear import pathway with SR proteins, RBM4 shuttles
between cytoplasm and nucleus but is mostly found in nuclear speckles (Lai et al., 2003)
where most splicing events occur. Consistently RBM4 was shown to control AS of Tau and
α-tropomyosin (Kar et al., 2006; Lin and Tarn, 2005). In addition, RBM4 was found to
affect translation (Lin and Tarn, 2009; Uniacke et al., 2012). Multiple physiological
functions were reported for RBM4, including mediating differentiation of muscle and
pancreas cells (Lin et al., 2007; Lin et al., 2013). However, the involvement of RBM4 in
tumorigenesis has not been reported. Here we systematically analyzed RBM4-mediated
changes of transcriptome and assessed the role of RBM4 in cancer progression.
Results
RBM4 is a sequence-specific splicing inhibitor that regulates various AS events
Previously we identified several groups of intronic splicing regulatory elements and their
cognate splicing factors (Wang et al., 2012; Wang et al., 2013). Among these factors, we
demonstrated that RBM4 specifically binds to the GTAACG motif to inhibit splicing from
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introns (Wang et al., 2012). In addition, another RBM4 binding motif (CGG repeats) was
also identified with CLIP-seq (Uniacke et al., 2012). Since AS is usually regulated in a
context dependent manner, we sought to examine how RBM4 controls splicing when bound
to distinct RNA motifs in different pre-mRNA contexts.
We generated four splicing reporters with candidate RBM4-binding motifs (GTAACG or
CGGCGG) inserted in different regions to examine if RBM4 can specifically alter their
splicing (Figure 1). First, we found that RBM4 specifically inhibited the inclusion of a
cassette exon containing its cognate binding sites, whereas the control reporter was not
affected (Figure 1A). Furthermore, RBM4 specifically suppressed inclusion of reporter exon
with a downstream RBM4 binding site (Figure 1B). These results suggest that RBM4
functions as a general splicing inhibitor to specifically suppress splicing from both exonic
and intronic contexts. Such activities are in contrast to DAZAP1, a splicing factor that
recognizes the same GTAACG site but functions as a splicing activator (Choudhury et al.,
2014). Interestingly, DAZAP1 does not affect splicing of exons containing a nearby
CGGCGG site (Figure S1A and S1B), suggesting a partial overlap of binding specificity and
an incomplete functional competition between RBM4 and DAZAP1.
Using splicing reporters containing RBM4-binding motifs between alternative 5′ ss or 3′ ss,
we found that RBM4 reduced the use of the downstream 5′ ss (Figure 1C) or upstream 3′ ss
(Figure 1D). The inhibition of distal alternative ss is again sequence specific, as RBM4
showed no effect on the control reporters (Figure 1C and 1D). Consistently, knockdown of
RBM4 with shRNA had opposite effects by increasing exon inclusion of the same splicing
reporters that contain RBM4-binding sites in various locations (Figure S1C–F). In addition,
similar results were obtained in a different cell type (e.g. HeLa cells), indicating that the
splicing regulation activity of RBM4 is not limited to a specific cell line (Figure S1G–J).
Together these data demonstrated that RBM4 is a general splicing inhibitor that controls
different types of AS when specifically binding to pre-mRNA.
Like many canonical splicing factors, RBM4 has a modular domain configuration. The N-
terminus contains two RNA recognition motifs (RRMs) and a CCHC-type zinc finger that
can specifically bind RNAs, while the C-terminus contains a low-complexity region (i.e.
Ala-rich stretches) that can interact with other proteins (Lin and Tarn, 2009) (Figure 1E). To
examine if RBM4 has a modular activity in splicing regulation, we fused the full-length, N-
or C-terminal fragments of RBM4 to another RNA binding domain PUF (Wang et al.,
2009). We co-expressed the fusion proteins with splicing reporters containing cognate PUF
targets inside an alternative exon (Figure 1F) or at downstream intron (Figure 1G) and
measured how splicing is affected. As expected, tethering the full length RBM4 to a target
site inside an alternative exon suppressed exon inclusion. Surprisingly, tethering either the
N- or C-terminal domain of RBM4 partially inhibited exon inclusion (Figure 1F), suggesting
that the RNA binding fragment and the low-complexity domain both serve as functional
modules. Such effect is sequence-specific, as these fusion proteins had no effect on control
reporters with a non-cognate target. Consistently, the full length RBM4 inhibited exon
inclusion when tethered to downstream of a cassette exon (Figure 1G). Interestingly, the N-
terminal fragment partially inhibited splicing from an intron, whereas the C-terminus
showed a slight splicing inhibitory activity (Figure 1G). Altogether, the N-terminal RNA-
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binding fragment and C-terminal low-complexity domain of RBM4 function cooperatively
to control different types of AS events in a sequence specific manner.
Global regulation of transcriptome by RBM4 in cancer-related genes
To gain further insight into RBM4-regulated AS events and thereby its physiological
functions, we conducted mRNA-seq with H157 cells expressing RBM4. With ~80 million
100-nt paired-end reads, we identified 473 RBM4-regulated AS events with an obvious
change of percent-spliced-in (PSI) values (PSI ≥ 0.15). Figure 2A shows the read tracks of
two examples. We found that various types of AS can be regulated by RBM4, including
skipped exon (SE), alternative 5′ ss exon (A5E), alternative 3′ ss exon (A3E), retained intron
(RI), mutually exclusive exons (MXE), and tandem UTR (TUTR) (Figure 2B, Table S1).
Subsequent analysis indicated that most of the AS events were negatively regulated by
RBM4 (decreased PSI value by RBM4 expression) (Figure 2C), consistent with our finding
that RBM4 suppressed splicing when directly binding to its pre-mRNA targets (Figure 1A to
1D).
We further analyzed RNA motifs in RBM4-regualted pre-mRNAs by extracting the
sequences near the RBM4-regulated SEs or between alternative 5′ ss of A5E. The relative
abundance of RBM4 binding motifs (GTAACG and CGGCGG) in these regions was
compared to control exons unaffected by RBM4 (Fairbrother et al., 2002). We found that
RBM4-binding motifs are enriched near the SEs or A5Es negatively regulated by RBM4
(Figure 2D), consistent with the model that RBM4 directly recognizes these pre-mRNAs to
control splicing. The AS events apparently promoted by RBM4 are likely due to indirect
effects, as these exons lack known RBM4 binding motifs (Figure 2D).
When analyzing cellular functions of RBM4-regulated AS events using gene ontology, we
found that RBM4 affects genes in RNA processing pathway including translation control,
RNA processing, and mRNA metabolic process (Figure 2E). Such functional enrichment is
not surprising since RBM4 is an RNA binding factor known to regulate splicing and
translation. Intriguingly, RBM4 targets are also enriched with cancer-related functions such
as regulation of NF-κB cascade and cell cycle. In addition, several RBM4-regulated AS
events were found to regulate the apoptotic pathway. Although this enrichment of apoptosis
is slightly below our significance cutoff, the changes of PSI value are fairly large and thus
may have significant functional consequences. Many of the RBM4-regulated splicing targets
were functionally connected into well-linked interaction networks as judged by STRING
(Search Tool for the Retrieval of Interacting Genes/Proteins) (Figure 2F). As expected, two
large subgroups of RBM4 targets contain genes in translation control and RNA processing.
Surprisingly, the other subgroup includes many genes in cell migration and adhesion (Figure
2F). Taken together, these results suggest that the biological processes affected by RBM4
are related to apoptosis, proliferation, migration and tumorigenesis.
We subsequently validated mRNA-seq results by measuring splicing change of 10 newly
identified targets, which were arbitrarily selected to include genes with cancer related
function. We confirmed that RBM4 either positively or negatively controls all endogenous
AS events tested (Figure 2G), and that the relative changes of PSIs obtained from RT-PCR
are highly correlated to those observed by mRNA-seq (Figure S2A, R2 = 0.6). These events
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were also validated in another cell line (HeLa) (Figure S2B), suggesting that RBM4 can
regulate AS with consistent activity across different cell types. In addition, we found that
knockdown of RBM4 caused opposite changes of splicing in endogenous RBM4 targets,
further confirming the reliability of our analyses (Figures S2C and S2D).
We also analyzed how RBM4 affects global gene expression. 185 genes were identified with
significant expression change (>2-fold with adjusted p < 0.05) (Table S2). These genes are
significantly associated with cancer related functions as judged by gene ontology (including
DNA replication, chemotaxis, cell proliferation, response to wounding, cell cycle, and cell
migration, Figure 2H), again suggesting that RBM4 is involved in cancer cell proliferation
and migration. Many RBM4-regulated genes were also functionally connected into a
densely-linked network that contains genes in regulating cell proliferation, wound healing,
cell cycle and DNA damage (Figure 2I). The selected RBM4 targets were further validated
with real time RT-PCRs in all events tested (Figure 2J). Taken together, all these data imply
that RBM4 may be a key regulator of cell proliferation and migration, thus to control cancer
progression.
RBM4 inhibits cancer cell proliferation and migration
To examine this possible role of RBM4 in cancer progression, we stably expressed RBM4 in
a panel of human cancer cells, including H157 (lung cancer), MDA-MB-231 (breast cancer),
SKOV3 (ovarian cancer), Panc-1 (pancreatic cancer), HepG2 (liver cancer), and PC-3
(prostate cancer) (Figure S3A). Strikingly, in all cancer cells tested, RBM4 inhibited
anchorage dependent or independent growth as judged by colony formation or soft agar
assay (Figure 3A). In addition, RBM4 inhibited cell migration of these cells in a would-
healing assay (Figure 3B). Together the inhibition of cancer cell proliferation and migration
by RBM4 suggests that it may function as a tumor suppressor.
We further analyzed how RBM4 affects cancer progression using NSCLC cells, which
represents one of the most prevalent human cancers. The RBM4 levels are markedly
decreased in a panel of NSCLC cells compared to normal bronchial cells (Figure 3C).
Consistently, when re-expressed in a NSCLC cell line H157, RBM4 significantly inhibited
cell growth (Figure 3D, p=0.02 by t-test). Similar growth inhibition by RBM4 was observed
in 293T cells (Figure S3B and S3C). Interestingly, although both N- and C-terminus of
RBM4 partially regulate splicing, lung cancer cell expressing either domain (1–177aa or
178–364aa of RBM4) displayed normal growth rates (Figure 3E), suggesting that both
domains are required to suppress tumorigenesis.
To further assess whether RBM4 affects cancer growth in vivo, we determined if RBM4 re-
expression can suppress tumor growth in a xenograft mouse model. We generated H157-luc-
RBM4 cells and control cells with lentiviral vectors, and subcutaneously injected them into
flanks of nude mice (left flank: RBM4; right flank: control). The growth of tumors was
measured every three days for five weeks, and xenograft tumors were removed for final
analysis. Consistent with the in vitro results, cells expressing RBM4 developed smaller
tumors as compared to control cells (Figure 3F and 3G). In addition, the xenograft tumors
with RBM4 re-expression grew much slower than controls (Figure 3H), suggesting that
RBM4 substantially inhibits cancer progression in vivo. Altogether these findings indicate
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that RBM4 is a potent tumor suppressor that inhibits lung cancer progression both in
cultured cells and in a tumor xenograft model.
RBM4 induces cancer cell apoptosis via regulating AS of Bcl-x
To determine the mechanisms of how RBM4 affects cancer progression, we focused on an
RBM4 target gene, Bcl-x, an apoptosis regulator that produces two splicing isoforms with
opposite functions. By alternative use of 5′ ss, Bcl-x is spliced as an anti-apoptotic isoform
(Bcl-xL) or a pro-apoptotic isoform (Bcl-xS) (Adams and Cory, 2007). RBM4 expression
appeared to shift the Bcl-xL into the Bcl-xS (Figure 2G). Such shift requires an entire
RBM4, as neither the N- nor C-terminus can affect Bcl-x splicing by itself (Figure S4A). We
identified a potential RBM4 binding site (CGGCGG) between the two alternative 5′ ss
(Figure 4A), implying that RBM4 may control splicing through directly binding to Bcl-x
pre-mRNA. Consistently, with an RNA-immunoprecipitation assay, we found that RBM4
indeed directly binds to the endogenous Bcl-x pre-mRNA but not the control pre-mRNA of
another alternatively spliced apoptotic gene (Mcl1) (Figure 4B). Using a splicing reporter
containing Bcl-x pre-mRNA, we found that the RBM4 binding is indeed dependent on the
CGGCGG site, as mutation of this site abolished RNA-protein interaction (Figure 4C).
Replacing the mutated sequence with the other RBM4-binding site (GTAACG) restored the
interaction, confirming that RBM4 directly recognizes the exon extension region of Bcl-x.
In addition to H157 cells, an inducible expression of RBM4 also shifted splicing of Bcl-x in
293 cells (Figure 4D). This shift caused a rapid and robust decrease of Bcl-xL protein as
judged by western blot (Figure S4B). To determine if the binding by RBM4 is responsible
for observed splicing shift, we co-transfected RBM4 with a series of Bcl-x reporters
containing various mutations near the alternative 5′ ss (Figure 4A). We found that RBM4
shifted the splicing of wild-type reporter by reducing Bcl-xL, and such regulation was not
affected by three exonic mutations (mutations 1 to 3) (Figure 4E). However, the mutation of
RBM4 binding site (mut 4) completely abolished the splicing regulation through RBM4,
indicating that the RBM4 binding motif (CGGCGG) is indeed responsible for Bcl-x splicing
switch. Importantly, replacing CGGCGG with another RBM4 binding site (mut 5) restored
the regulation by RBM4 (Figure 4E), suggesting that binding of RBM4 to Bcl-x pre-mRNA
is sufficient to shift splicing.
The two splicing isoforms of Bcl-x have opposite functions in controlling apoptosis (Adams
and Cory, 2007). The Bcl-xL is the predominant isoform in cancer, and RNAi of Bcl-xL was
shown to induce apoptosis in several cancer cell lines (Mercatante et al., 2001; Zhu et al.,
2005). We found that expression of RBM4 in H157 cells substantially reduced the level of
Bcl-xL protein, resulting in the cleavage of caspase 3 and PARP, two molecular markers of
apoptosis (Figure 4F). Consistently, RBM4 dramatically increased spontaneous apoptosis as
judged by flow cytometry (Figure 4G and Figure S4C). These results support the model that
sequence-specific binding of RBM4 to Bcl-x pre-mRNA shifts its splicing from anti-
apoptotic Bcl-xL to pro-apoptotic Bcl-xS, thereby promoting cancer cell death.
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RBM4 suppresses tumor progression in part through Bcl-x
Since RBM4 may inhibit cancer proliferation through modulating Bcl-x splicing, we next
examined if co-expression of Bcl-xL, but not other similar apoptotic regulators, can overturn
the tumor suppressor activity of RBM4. We stably transfected the parental H157 line
containing re-expressed RBM4 with Bcl-xL or another apoptotic inhibitor Mcl-1 (Figure
5A), generating a cell line with partially restored Bcl-xL/Bcl-xS ratio and reduced PARP
cleavage (Figure 5B). We found that cells expressing RBM4/Bcl-xL grew much faster than
those expressing RBM4 alone, although the growth rate was not fully restored compared to
control (Figure 5C). However cells expressing RBM4/Mcl-1 showed a similar growth rate as
compared to cells expressing RBM4 alone (Figure 5C), indicating such phenotypical rescue
is specific for Bcl-xL. In addition, cancer cells expressing RBM4/Bcl-xL migrated
significantly faster than cells expressing RBM4 alone or RBM4/Mcl-1 (Figure 5D), again
suggesting that restoring Bcl-xL level partially reversed the RBM4 phenotype. Consistently,
the xenograft tumors generated from RBM4/Bcl-xL cells are significantly larger than those
from RBM4/vector cells, indicating that reducing Bcl-xL level is partially responsible for
RBM4-mediated tumor suppression in vivo (Figure 5E). This phenotypic rescue is robust
and statistically significant, although it could not fully restore tumor progression probably
due to partial reverse of Bcl-xL/Bcl-xS ratio (Figure 5B).
We further applied a specific Bcl-xL inhibitor (WEHI-539) in cells expressing RBM4 and
examined its effect on cell growth. Consistent with previous reports (Lessene et al., 2013),
WEHI-539 did not significantly affect the viability of control cells. However, WEHI-539
treatment inhibited the proliferation of RBM4-expressing cancer cells as compared to
untreated cells (Figure 5F and 5G). Such apparent synergistic effect may reflect two
mechanisms that are not mutually exclusive: (1) Through splicing regulation, RBM4 reduces
the level of Bcl-xL to the extent where the WEHI-539 can have a detectable effect; (2)
RBM4 inhibits cell proliferation through other mechanisms in addition to reducing anti-
apoptotic Bcl-xL, whereas WEHI-539 specifically inhibits Bcl-xL. By targeting parallel pro-
survival pathways, the combination of RBM4 and WEHI-539 synergistically suppressed
cancer cell proliferation.
Consistently, we found an increased expression of Bcl-xL in lung cancers, breast cancers
and pancreatic cancers, which is inversely correlated to RBM4 level (Figure 5H, S5A and
S5B). This finding further supported that RBM4 inhibits tumor progression (at least
partially) via controlling Bcl-x splicing.
RBM4 antagonizes oncogenic SRSF1 to inhibit mTOR activation
Although our data clearly demonstrate that RBM4 suppresses cancer progression by
modulating Bcl-x splicing, this may not be the only mechanism as co-expression of Bcl-xL
partially reversed the phenotype of RBM4. To eliminate the apoptosis effect, we treated
cells with a pan-caspase inhibitor, Z-VAD. We found that, even when the apoptosis was
strongly inhibited (Figure 6A), proliferation and migration of cancer cells were still
significantly suppressed by RBM4 (Figure 6B). This observation suggests that RBM4 might
also inhibit cancer progression through other mechanisms besides regulating apoptosis.
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It was previously reported that the general splicing factor SRSF1 functions as proto-
oncogene to transform rodent fibroblasts (Karni et al., 2007). We found that RBM4
interacted with SRSF1 in a co-IP assay (Figure S6A). Remarkably, RBM4 can reduce the
protein level of SRSF1 in a dose dependent manner (Figure 6C). Such inhibition is specific
to SRSF1, as two other splicing factors, DAZAP1 and hnRNPA1, were not affected (Figure
6C). Similar results were also obtained in a cell line with inducible expression of RBM4
(Figure S6B). Since SRSF1 is a well-characterized oncogenic factor to promote
tumorigenesis through multiple pathways (Anczukow et al., 2012; Karni et al., 2007), our
observation suggests that RBM4 may also inhibit cancer progression via antagonizing
SRSF1.
SRSF1 was known to control multiple AS events that promote tumorigenesis (Anczukow et
al., 2012; Karni et al., 2007). For example, BIN1 is a tumor suppressor that binds to MYC
(Sakamuro et al., 1996), and SRSF1 promotes inclusion of BIN1 exon 12a to generate a
BIN1+12 isoform that lacks tumor suppressor activity (Karni et al., 2007); SRSF1 also
inhibits the exclusion of exon 11 in RON, generating RONΔ11 that promotes cell migration
and invasion (Anczukow et al., 2012). We examined whether RBM4 could affect the
splicing of cancer-related SRSF1 targets using cells stably expressing SRSF1, RBM4, or
SRSF1/RBM4. As expected, RBM4 regulated splicing of both BIN1 and RON in an
opposite fashion to SRSF1, shifting their splicing towards anti-oncogenic isoforms (Figure
6D and S6C).
SRSF1 was also reported to activate mTOR pathway by increasing phosphorylation of S6K1
and 4E-BP1, as well as promoting oncogenic S6K1 splicing isoform 2 (Karni et al., 2007;
Karni et al., 2008). Co-expression of RBM4 with SRSF1 substantially inhibited SRSF1-
induced mTOR activation, as judged by the dramatic reduction in the phosphorylation of
S6K1 and 4E-BP1 (Figure 6E). However, phosphorylation of two upstream components of
mTOR signaling pathway, Akt and Erk, are not affected by RBM4. Interestingly, co-
expression of RBM4 also reduced the S6K1 isoform 2 (Figure 6E and S6D), an SRSF1-
induced oncogenic variant that induces cell transformation through activating mTOR
pathway (Ben-Hur et al., 2013).
In addition, expression of RBM4 alone also inhibits the insulin-induced mTOR activation as
judged by reduced phosphorylation of S6K1, 4E-BP1, and mTOR itself (Figure 6E). The
phosphorylation of Erk and Akt was not affected, suggesting that RBM4 controls
downstream stages of mTOR activation. This observation indicates that RBM4 can also
directly inhibit mTOR activation. Since mTOR pathway plays key roles in promoting cell
proliferation, inhibition of mTOR by RBM4 probably contribute to its tumor suppressor
activity.
SRSF1 is also predicted to bind the same CGGCGG site in Bcl-x pre-mRNAs (Figure S6E
and 4A), indicating that RBM4 and SRSF1 may counteract with each other in tuning the
Bcl-x splicing switch. We co-expressed the Bcl-x splicing reporters (wild-type and
CGGCGG mutation) with RBM4, SRSF1, or RBM4/SRSF1. As expected, SRSF1 promoted
the anti-apoptotic Bcl-xL isoforms, whereas RBM4 reduced Bcl-xL. In addition, co-
expression of RBM4 can overturn the activity of SRSF1 to increase the pro-apoptotic Bcl-xS
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isoform (Figure 6F). Consistently, when the binding site (CGGCGG) was mutated, the
splicing regulation of Bcl-x by both RBM4 and SRSF1 were abolished, confirming that they
control Bcl-x splicing through competing the same regulatory element.
We further applied colony formation and soft agar assays with cancer cells expressing
SRSF1 and SRSF1/RBM4. Compared to controls, H157 cells expressing SRSF1 formed
more and larger colonies in both assays, whereas co-expression of RBM4 with SRSF1
significantly reduced colony number and size (Figure 6G), indicating that RBM4 could
inhibit cancer cell proliferation through antagonizing SRSF1.
RBM4 is reduced in NSCLC patients and positively correlated with survival
To further study the role of RBM4 as a tumor suppressor, we examined its clinical relevance
in cancer patients. We first analyzed the microarray dataset from various large-scale studies
(Buchholz et al., 2005; Finak et al., 2008; Selamat et al., 2012), and found that tumors
collected from NSCLC patients have significantly decreased RBM4 level compared to
normal controls (Figure 7A). Similar reduction of RBM4 was also observed in other cancers,
including breast and pancreatic cancer (Figures S7A and S7B), consistent with the notion
that RBM4 is a tumor suppressor in various human cancers.
Next we surgically collected paired NSCLC samples and adjacent normal tissues from seven
patients to measure RBM4 levels. We found that, compared to the paired normal tissues, all
7 primary NSCLC specimens have substantially reduced RBM4 expression in the level of
mRNA and protein (Figure 7B and 7C). Such reduction was independently validated by
immunohistochemistry assay of 110 clinical samples (Figure 7D and 7E). We found that,
compared to non-cancerous tissues (n=40), RBM4 was noticeably reduced in both lung
squamous cell carcinoma (n=30) and adenocarcinoma (n=40): The RBM4 staining was
undetectable in 57 of 70 (81%) NSCLC samples, and weak staining was detected in 13
tumors (19%). In contrast, most normal lung samples (39 of 40) exhibited strong or weak
staining for RBM4.
Compared to paired normal tissues, the splicing of Bcl-x is shifted in tumor samples with
Bcl-xL being the predominant isoform (Figure 7F). In addition, the protein levels of Bcl-xL
and SRSF1 are substantially increased in NSCLC samples as compared to paired normal
tissues (Figure 7G), further supporting our findings using cultured cancer cells. Taken
together, these clinical observations strongly support the RBM4-mediated tumor suppression
model derived from cell culture and animal studies.
To further investigate the clinical significance of RBM4 in lung cancers, we used a survival
analysis tool, Kaplan-Meier Plotter, to analyze the overall survival of cancer patients with
different RBM4 levels using datasets from GEO, EGA and TCGA consortium (Gyorffy et
al., 2012). Strikingly, higher expression of RBM4 was closely associated with improved
overall survival in patients with lung cancers (Figure 7H), breast cancers (Figure S7C), and
ovarian cancers (Figure S7D), indicating that RBM4 might be recognized as an independent
prognostic factor for cancer survival. This result validated the mechanistic link between
reduced expression of RBM4 and cancer progression, supporting the conclusion that
reduced RBM4 expression affects human cancer progression and patient survival.
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Previously RBM4 was reported to promote inclusion of alternative exons in tau and α-
tropomyosin (Kar et al., 2006; Lin and Tarn, 2005). Using various reporters we demonstrate
that RBM4 predominantly functions as a splicing suppressor when directly bound to pre-
mRNA. Over-expression of RBM4 in H157 cells inhibited exon inclusion in ~60% of
cassette exons detected, further supporting RBM4’s role as a splicing suppressor. However,
a smaller fraction of AS events are positively regulated by RBM4, and we speculate that the
splicing enhancement by RBM4 is likely a result of more complicated mechanisms other
than direct binding between pre-mRNA and RBM4 (such as indirect effects through other
genes, RNA structures, or by functioning together with other splicing factors). For example,
RBM4 promoted exon inclusion of RON (Figure 6D and S6C), which probably is due to an
indirect effect resulted from reduction of SRSF1 by RBM4.
Both N-terminal RNA-binding fragment or C-terminal low-complexity domain of RBM4
were sufficient to inhibit splicing from exons, while the N-terminal fragment had partial
splicing inhibitory activity from introns. These results present an unusual regulatory mode
compared to typical splicing factors. Many splicing factors, like SR proteins, hnRNP A1,
and DAZAP1, contain a separate RNA binding module to recognize targets and an
independent functional module to control splicing (Choudhury et al., 2014; Del Gatto-
Konczak et al., 1999; Graveley and Maniatis, 1998). RBM4 may represent another class in
which both fragments can inhibit splicing but the entire protein harbors a stronger activity,
indicating that the two fragments cooperatively control splicing rather than function in a
modular fashion.
Besides splicing regulation, RBM4 was also shown to regulate translation by suppressing
cap-dependent translation (Lin and Tarn, 2009), activating internal ribosomal entry site
(IRES)-mediated translation under cell stress (Lin et al., 2007), or mediating an oxygen-
regulated translation switch (Uniacke et al., 2012). As an RNA binding protein shuttling
between the nucleus and cytoplasm, it is possible that RBM4 may affect cell growth through
controlling both translation and splicing. Future investigations should be conducted to
determine whether the translation regulation by RBM4 contributes to its tumor suppression
and how such process interacts with splicing regulation.
Our results support a model that RBM4 shifts splicing of Bcl-x to control the balance
between pro- and anti- apoptotic pathways, and thus suppresses cancer progression.
Consistently, the shift of Bcl-x splicing is correlated with RBM4 reduction in cancer
patients, and co-expressing the anti-apoptotic variant Bcl-xL partially reverses the tumor
suppression by RBM4 in vitro and in mouse models. Since the splicing switch of Bcl-x is
associated with many cancers to protect cancers against apoptotic signals (Danial, 2007),
modulating Bcl-x splicing has been shown to be a potential therapeutic intervention for
cancer (Bauman et al., 2010; Shkreta et al., 2008; Villemaire et al., 2003).
Other RBM4-regulated events may also contribute to tumor pathogenesis and progression.
With genomic analyses we found RBM4 affected many other AS events in cell metabolism
and cell cycle regulation. For example, RBM4 affects splicing of CD44, which is known to
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mediate cell migration, tumor progression and metastasis (Williams et al., 2013). The choice
of CD44 splicing variants has long been found with oncogenic roles in different cancers
(Brown et al., 2011; Yae et al., 2012). These results suggest that RBM4 mediates multiple
AS events critical to cancer progression. As a master regulator of cancer-related AS, RBM4
potentially inhibits tumorigenesis through multiple oncogenic pathways, which helps to
explain why co-expression of Bcl-xL partially reversed the phenotype of restoring RBM4
level in cancer.
In addition to regulating Bcl-x splicing, RBM4 probably also inhibits tumor progression by
antagonizing SRSF1 that is known to promote cell proliferation and delay apoptosis. The
reduction of SRSF1 by RBM4 inhibits the oncogenic activity of several SRSF1 targets,
including the proto-oncogene RON and tumor suppressor BIN1. More importantly, RBM4
counteracts with SRSF1 to mediate the activation of mTORC1 pathway. Taken together, the
antagonism between two splicing factors, tumor-suppressor RBM4 and proto-oncogene
SRSF1, presents a delicate functional balance that controls multiple splicing targets and
signaling pathways critical to cancer proliferation.
Splicing dysregulation was recently been recognized as a major molecular hallmark of
human cancer (David and Manley, 2010; Oltean and Bates, 2013). Some dysregulated AS
events can serve as molecular markers of cancer, while others may be directly responsible
for tumorigenesis. Therefore a mechanistic study of splicing mis-regulation will provide
new insights in cancer. This study represents an important example of how a splicing factor
can control critical AS events in cancer progression. In addition, re-expression of RBM4 can
inhibit tumor growth both in cell culture system and in mouse models, suggesting that
restoration of RBM4 activity may provide an attractive route for future therapy.
Experimental Procedures
Cell culture and splicing assay
HEK 293T, HeLa, and H157 cells were maintained at standard culture conditions (37°C, 5%
CO2) in culture medium recommended by ATCC. To generate stable cells that express
RBM4, the ORF was cloned into pcDNA5/FRT/TO and resulting vector was co-transfected
with pOG44 plasmid into the Flp-In T-REx 293 cells (Life Technologies). Similarly stable
H157 cells were created using lentiviral vector (pCDH cDNA cloning and expression
lentivectors, System Biosciences, Inc.). Semi-quantitative RT-PCR was performed as
described previously (Wang et al., 2013), and were quantified using Image Quant
Software™ (GE Health Care). See supplementary methods for more details.
Clinical tissues samples collection
Fresh tumor tissues and normal adjacent tissues were collected from patients with
pathologically and clinically confirmed carcinomas. All human tumor tissues were obtained
with written informed consent from patients or their guardians prior to participation in the
study. The Institutional Review Board of the Dalian Medical University approved use of the
tumor specimens in this study. Most of tissue samples were fixed in formalin, embedded in
paraffin, and sectioned at 5 µm. One section was stained with H&E for histological
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examination, and the others were used for immunohistochemistry staining. A portion of
tissue specimens were kept in liquid nitrogen and sectioned for protein or mRNA extraction.
Xenograft Assays
The Institutional Animal Care and Use Committee of the Dalian Medical University
approved the experimental protocols performed on the animals. Female nude mice were
purchased from Vital River Laboratories (VRL) for subcutaneous xenograft experiments.
H157-luc-RBM4 and control cells were injected subcutaneously (1×106 cells). Tumor size
was measured by caliper every three days.
RNA seq analysis
Cell lines stably expressing RBM4 or control vector were created, and the total RNA was
purified from the cells using TRIzol reagents. The polyadenylated RNAs were purified from
the cell lines for construction of sequencing library using Illumina TruSeq Total RNA
Sample Prep kits (UNC High Throughput Sequencing Facility). The paired-end reads were
generated by the Illumina Hi-Seq 2000 platform and mapped to human genome. Changes of
splicing isoforms were analyzed by MISO pipeline. The sequencing data were deposited in
GEO repository with accession number GSE58594.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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• RBM4 controls various types of splicing in a sequence-specific manner
• RBM4 regulates various cancer-related genes and suppresses tumorigenesis
• RBM4 inhibits cancer by antagonizing oncogenic SRSF1 and regulating Bcl-x
splicing
• RBM4 is reduced in cancer patients and positively correlated with improved
survival
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Aberrant splicing is closely associated with human cancers, however the mechanistic
details underlying these connections are largely unknown. Investigating splicing factors
that play vital roles in cancer progression would enable therapeutic targeting of
deregulated splicing and open new avenues for cancer therapy. Here we systematically
dissect an RBM4-mediated splicing regulation pathway that is closely related to cancer
progression. We uncover that the splicing factor RBM4 suppresses tumor progression by
balancing the pro- and anti-apoptotic signals through splicing regulation and by
antagonizing the oncogenic splicing factor SRSF1. The clinical relevance of such
regulation is further revealed. This study represents a detailed mechanism of cancer-
related splicing dysregulation, and establishes RBM4 as a tumor suppressor with
therapeutic potentials.
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Figure 1. Splicing regulation by RBM4
(A) The RBM4 binding site and a control (GAATTG) were inserted into splicing reporter
pGZ3 that were co-transfected with RBM4 expression vector or empty vector (mock) into
293T cells. Splicing changes were examined by electrophoresis of RT-PCR products. (B)
The same set of sequences analyzed in A were inserted downstream of a cassette exon in the
pZW2C reporter to measure splicing changes as in A. (C–D) The same set of RBM4-
binding sequences analyzed in A were inserted into the splicing reporters between two
tandem sites with competing 5′ (C) or 3′ ss (D) and splicing changes were measured as in A.
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(E) Schematics of RBM4 domains. R1R2Z fragment contains two RRM domains and a
Zinc-finger domain. The PA fragment contains poly-alanine stretch. (F–G) Different RBM4
fragments were fused to a PUF domain, PUF(3–2), which specifically binds to its target
RNA. The fusion proteins were co-transfected with a splicing reporter containing PUF
binding site or a control (Ctl) site in a cassette exon (F) or at downstream intron (G) and
splicing changes were measured as in A. In all panels measuring changes in splicing,
expression of exogenous protein was confirmed by western blots. Tubulin served as a
protein loading control. Three independent experiments were conducted, with the mean +/−
SD of PSIs plotted below representative gels. The arrowhead indicates a non-specific
product. Asterisks indicate p<0.05 by t-test. See also Figure S1.
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Figure 2. Global splicing and transcriptional regulation by RBM4
(A) Examples of alternative exons affected by RBM4. Genes were chosen to represent both
an increase and a decrease of PSI, and numbers of exon junction reads were indicated. (B)
Quantification of the different AS events affected by RBM4. (C) The relative fraction of
each AS event positively or negatively affected by RBM4. (D) Relative enrichment of the
indicated RNA motifs bound by RBM4. Enrichment scores were computed by comparing
RBM4-regulated SEs or A5Es with control AS events unaffected by RBM4. The AS events
with increased or decreased PSI values upon RBM4 expression were analyzed separately.
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(E) Gene ontology of RBM4-regulated AS targets. Fisher exact p-values were plotted for
each enriched functional category. (F) Functional association network of RBM4-regulated
AS targets. Genes in panel E were analyzed using the STRING database, and subgroups are
marked according to their functions. (G) Validation of different types of RBM4-regulated
AS events by semi-quantitative RT-PCR using H157 cells transfected with RBM4 or control
vectors. The mean +/− SD of PSIs from three experiments were plotted (p values from
paired t-test). (H) Gene ontology analyses of RBM4-regulated gene expression events.
Fisher exact p values were plotted for each category. (I) The functional association networks
of RBM4-regulated genes were analyzed using the STRING database, with subgroups
marked by their functions. (J) Validation of gene expression changes by real-time RT-PCR.
The mean +/− SD of relative fold changes from triplicate experiments were plotted with p
values calculated by paired t-test. See also Figure S2 and Tables S1 and S2.
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Figure 3. RBM4 inhibits cancer progression
(A) RBM4 effects on the proliferation of various cancer cells, including H157, MDA-
MB-231, SKOV3, Panc-1, HepG2, and PC-3. The cells were stably transfected with RBM4
or vector control and analyzed by colony formation (upper panel) or soft agar (lower panel)
assays. All experiments were performed in triplicates, with mean +/− SD of relative colony
numbers plotted (p values from t-test). Scale bar = 100 µm in lower panels. Images of the
whole plate are shown in upper panel. (B) Different cancer cell lines expressing RBM4 or
vector control were analyzed by wound healing assay. Percent of wound closure was
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measured from triplicate experiments, with mean +/− SD plotted (p values from t-test).
Scale bar = 200 µm. (C) Levels of RBM4 in the indicated NSCLC cell lines and normal
bronchial cells were measured by western blot. (D) H157 cells stably expressing RBM4 or
vector control were grown for 9 days, with cell numbers counted every two days. The
changes of cell numbers were compared to day 0. The mean +/− SD from three experiments
was plotted. (E) H157 cells expressing full length (FL), or the N- or C-terminal fragments of
RBM4 were analyzed by colony formation assay. Representative pictures of the whole
plates from triplicate experiments are shown. The mean +/− SD of relative colony numbers
were plotted, with p values calculated by t-test. (F) H157-luc-RBM4 and control cells were
subcutaneously injected into left and right flank of seven nude mice. The growth of
xenograft tumors was monitored by bioluminescence imaging on day 3 and 35, and pictures
of two representative mice were shown. (G) Pictures of the tumors removed after 35 days.
(H) The average sizes of xenograft tumors measured every three days (n=7, error bars
indicate +/− SD, p<0.05 by t-test). See also Figure S3.
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Figure 4. RBM4 regulates Bcl-x splicing to induce apoptosis
(A) The schematic of Bcl-x pre-mRNA where the potential RBM4-binding site in red. Bcl-x
splicing reporters with the indicated mutations (mut1 to 5) were generated. (B) Binding of
Bcl-x pre-mRNAs with RBM4 is detected by RNA-immunoprecipitation assay in cells
exogenously expression FLAG-RBM4 or vector control. The binding of Mcl-1 mRNA was
used as specificity control. (C) 293 cells were co-transfected with Flag-RBM4 or vector
control and the indicated mutant or wild-type (WT) Bcl-x reporters, and then
immunoprecipitated with anti-Flag antibody. The co-precipitated RNAs were detected by
RT-PCR. (D) 293 cells containing tetracycline-inducible RBM4 or vector control were used
to measure Bcl-x splicing. Increased levels of Bcl-xS in uninduced cells are likely due to
expression leakage. The mean +/− SD of PSI from triplicate experiments were plotted. (E)
Bcl-x splicing reporters containing various mutations were co-expressed with RBM4 or
vector control in 293T cells to assay for the splicing change of Bcl-x. The mean +/− SD of
Bcl-xS% was plotted. A representative gel from triplicate experiments was shown. (F) H157
cells expressing RBM4 or vector control were used to examine apoptotic markers including
Bcl-xL, cleaved caspase 3 and PARP. (G) Expression of RBM4 promotes apoptosis. H157
cells expressing RBM4 or control were stained with propidium iodide and the apoptotic cells
were detected by flow cytometry. The mean +/− SD of percentage of apoptotic cells from
triplicate experiments were plotted. See also Figure S4.
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Figure 5. RBM4 regulates Bcl-x splicing to inhibit cancer progression
(A) H157 cells with stable co-expression of RBM4/Bcl-xL, RBM4/Mcl-1 or RBM4/vector
control were generated. The protein expression was confirmed by western blot. (B) Splicing
of Bcl-x in H157 cells expressing RBM4/Bcl-xL, RBM4, RBM4/Mcl-1 or vector control
was measured by semi-quantitative RT-PCR. The mean +/− SD of Bcl-xS% from three
experiments was plotted. PARP cleavage was examined by western blot. (C) Colony
formation assays using H157 cells expressing RBM4, RBM4/Bcl-xL, RBM4/Mcl-1 or
vector control. Images of the whole plate are shown. Three experiments were carried out
with mean +/− SD of relative colony numbers plotted (p values were determined by t-test).
N.S. = not significant. (D) Wound healing assay of H157 cells expressing RBM4, RBM4/
Bcl-xL, RBM4/Mcl-1 or vecor control. The means +/− SD of wound closure were plotted (p
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values were calculated by t-test). Scale bar = 200 µm. (E) Xenograft tumors were generated
using nude mice injected with H157-luc-control, H157-luc-RBM4/Bcl-xL, or H157-luc-
RBM4 cells. Tumors were removed after five weeks, and tumor volume was quantified. The
median, upper and lower quartiles of tumor volume were plotted as box plot, with whiskers
indicating data range. The points that are >1.5×interquartile range are marked outliers. (F–
G) H157 cells expressing RBM4 or vector control were treated with or without the Bcl-xL
inhibitor WEHI-539. The resulting cells were analyzed by colony formation (F) and
anchorage-independent growth (G) assays. Three experiments were carried out with the
mean +/− SD of relative colony numbers plotted (p values from t-test). Images of the whole
plate are shown in panel F. Scale bar = 100 µm in panel G. (H) Inverse correlation of Bcl-x
and RBM4 in lung cancer patients. Oncomine was used to analyze expression data. The
mean levels of Bcl-xL and RBM4 were plotted, error bars indicate upper and lower quartile.
See also Figure S5.
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Figure 6. RBM4 antagonizes SRSF1 to inhibit cancer cell growth
(A) H157 cells expressing RBM4 were treated with Z-VAD or DMSO control. The
apoptotic markers, cleaved PARP and caspase 3, were examined by western blot. (B) H157
cells expressing RBM4 with or without Z-VAD treatment were analyzed by colony
formation, soft agar, and wound healing assays. The experiments were performed in
triplicate, and representative pictures are shown. The p values calculated by t-test. Images of
the whole plate are shown in upper panel. Scale bar = 200 µm. (C) H157 cells were
transiently transfected with increasing amounts of RBM4 and examined by western blot for
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protein levels of SRSF1, DAZAP1, hnRNP A1, and RBM4. (D) H157 cells expressing
SRSF1, SRSF1/RBM4, or control were collected to examine splicing of SRSF1 targets,
BIN1 (left) and RON (right), by semi-quantitative RT-PCR. (E) The levels of mTOR and
various mTOR targets were examined in H157 cells expressing SRSF1, SRSF1/RBM4, or
control vector using western blots. Cells expressing RBM4 or control were also treated with
insulin for 30 min to measure activation of mTOR pathway. (F) Bcl-x splicing reporters
(WT and mut4 in figure 4A) were co-expressed with RBM4, SRSF1, or both to examine its
splicing by RT-PCR. (G) The colony formation and soft agar assays using H157 cells
expressing SRSF1, SRSF1/RBM4, or control. Three experiments were carried out. The p
values were calculated by t-test. Images of the whole plate are shown in upper panel. Scale
bar = 100 µm. In panels B, D, F, and G, the means +/− S.D. are plotted. See also Figure S6.
Wang et al. Page 28






















Figure 7. RBM4 in NSCLC patients
(A) RBM4 mRNA level in lung cancer patients as reported from Oncomine. The median,
upper and lower quartiles were plotted, and the whiskers indicate the data range. The points
that are >1.5×interquartile range are marked outliers. (B) Total RNA isolated from paired
NSCLC tumors and adjacent normal tissues were assayed by real-time RT-PCR. (C) RBM4
levels from seven paired NSCLC tumors (T) and normal (N) tissues were analyzed by
western blot. The p value was calculated by t-test. (D) Normal lung tissues and NSCLC
samples were collected and subjected to immunohistochemical staining with an RBM4
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antibody. Scale bar = 40 µm. (E) The quantification of RBM4 protein levels in normal lung,
lung squamous carcinoma and lung adenocarcinoma. The RBM4 levels were classified into
three grades (negative, weak positive, strong positive) by results from immunohistochemical
staining and plotted. (F) Splicing of Bcl-x in paired NSCLC tumor and adjacent normal
tissue. (G) Protein levels of Bcl-xL and SRSF1 in the paired tumor and adjacent normal
tissues. (H) Kaplan-Meier curve showing overall survival of lung cancers with high or low
RBM4 expression (p=3.9e-10 by log-rank test). Error bars indicate +/− S.D. in panels C and
F. See also Figure S7.
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